CClinicalTrials.gg
CompletedNCT05879393ProURTIUpdated Jun 5, 2023

The Multistrain Probiotic OMNi-BiOTiC® Active for Upper Respiratory Tract Infections in Older People

An interventional study of OMNi-BiOTiC® Active and Placebo in Acute Upper Respiratory Tract Infection, sponsored by University Maribor. Completed at 1 site in Slovenia. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by University Maribor · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this randomised controlled trial is to determine the effect of consuming a multistrain probiotic OMNi-BiOTiC® Active to shorten the incidence and duration of acute upper respiratory tract infections (URTIs) in older people. The main questions it aims to answer is:

  • Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the incidence of URTIs in older people?
  • Is the multistrain probiotic OMNi-BiOTiC® Active effective in reducing the duration of URTIs in older people?
  • Is the multistrain probiotic OMNiBiOTiC® Active effective in changing selected immunological blood parameters in older people? Researchers will compare the probiotic group and the placebo group to see if the incidence or duration of URTIs are significant among the groups.
02

Conditions studied

  • Acute Upper Respiratory Tract Infection
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 65 years or older at the signing of the written consent form
  • ability of participant to eat independently
  • ability of participant to adhere to all procedures of the clinical study

Exclusion criteria

Exclusion Criteria:

  • participants experienced an exacerbation of an existing chronic disease
  • participants experienced an exacerbation of metabolic diseases,
  • participants with mental incapacity to understand instructions
  • participants were prescribed long-term usage of antibiotics.
  • participants that changed their eating habits or consumed any probiotics 14 days
  • participants with markedly abnormal results of blood tests were excluded.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Multistrain Probiotic OMNi-BiOTiC® Active

    Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, Ligilactobacillus salivarius W24, Levilactobacillus brevis W63, Lactococcus lactis W58, Lactococcus lactis W19, Bifidobacterium animalis subsp. lactis W52, Bifidobacterium longum subsp. longum W108, Bifidobacterium breve W25, Bifidobacterium animalis subsp. lactis W51 and Bifidobacterium bifidum W23. Additional ingredients:corn starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate and vanillin

    Dietary Supplement: OMNi-BiOTiC® Active

  • Placebo comparator
    Placebo

    rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate

    Other: Placebo

Interventions

  • Dietary supplementOMNi-BiOTiC® Active

    Multistrain probiotic

  • OtherPlacebo

    rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate

05

What researchers measure

Primary outcomes

  1. Incidence of URTI

    Comparison of the incidence of acute upper respiratory tract infections among older people in both arms

    Time frame: 12 weeks supplementation

Secondary outcomes

  1. Duration of URTI

    Comparison of the duration of acute upper respiratory tract infections among older people in both arms via the use of a questionnaire

    Time frame: 12 weeks supplementation

  2. Changes in concentration of leukocytes, neutrophils segm., lymphocytes, monocytes, eosinophils, basophils in serum

    Differences in the serum concentration of leukocytes, neutrophils segm., lymphocytes, monocytes, eosinophils, basophils, measured in 10x9/L of the participants in the first winter season as a change from baseline to 12 weeks upon administration of probiotics compared to placebo

    Time frame: 12 weeks supplementation

  3. Changes in concentration of Immunoglobulin A (IgA) in serum

    Differences in the serum concentration of immunoglobulin A (IgA), measured in g/L of the participants in the first winter season as a change from baseline to 12 weeks upon administration of probiotics compared to placebo

    Time frame: 12 weeks supplementation

06

Study locations

1 site
  • University of Maribor, Faculty of Health Sciences
    Maribor, 2000, Slovenia
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05879393
Lead sponsor
University Maribor
Responsible party
Sabina Fijan (Assoc. prof. dr., University Maribor) — Principal investigator
First posted
May 30, 2023
Start date
Oct 7, 2020
Primary completion
Feb 13, 2022
Completion
Jul 13, 2022
Last update
Jun 5, 2023

Study contacts

Sabina Fijan, Ph.D
study director · University of Maribor, Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion